Indication
Hyperlipoproteinemia
3 clinical trials
3 products
1 drug
Product
PelacarsenClinical trial
A Randomized, Double-blind, Placebo-controlled, Multicenter Trial Assessing the Reduction of the Rate of Lipoprotein Apheresis After Treatment With Pelacarsen (TQJ230) Compared to Placebo in Patients With Hyperlipoproteinemia(a) and Established Cardiovascular Disease Undergoing Weekly Lipoprotein Apheresis in GermanyStatus: Active (not recruiting), Estimated PCD: 2025-06-27
Product
Corresponding PlaceboClinical trial
A Single Arm, Open Label Extension (OLE), Multicenter Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) in Patients With Cardiovascular Disease Who Have Successfully Completed the Apheresis Parent Study.Status: Recruiting, Estimated PCD: 2028-08-24
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3561774 in Adults With Mixed DyslipidemiaStatus: Active (not recruiting), Estimated PCD: 2024-03-04
Product
LY3561774Drug
Varlilumab